Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.,Pigment Cell & Melanoma Research

当前位置： X-MOL 学术 › Pigment Cell Melanoma Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.
Pigment Cell & Melanoma Research ( IF 3.9 ) Pub Date : 2020-06-21 , DOI: 10.1111/pcmr.12909
Kimberly Loo _{1,

2} , Gabrielle Gauvin ₁ , Iman Soliman ₁ , Madelyn Renzetti _{1,

2} , Mengying Deng ₃ , Eric Ross ₃ , Biao Luo ₄ , Hong Wu ₄ , Sanjay Reddy ₁ , Anthony J Olszanski ₅ , Jeffrey M Farma ₁

Affiliation

Considerable advances in melanoma have been realized through immunotherapy. The principal aim was to determine whether primary tumor characteristics or next‐generation sequencing (NGS) could serve as markers of immunotherapy response.

中文翻译：